Sai Life Sciences Limited (NSE:SAILIFE)

Market Cap	336.20B +86.5%
Revenue (ttm)	22.50B +17.7%
Net Income	3.62B +48.2%
EPS	17.02 +43.2%
Shares Out	212.12M
PE Ratio	93.12
Forward PE	75.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,169,848
Open	1,590.00
Previous Close	1,591.10
Day's Range	1,571.40 - 1,616.10
52-Week Range	783.85 - 1,697.00
Beta	n/a
Analysts	Buy
Price Target	1,552.67 (-2.04%)
Earnings Date	Nov 6, 2026

About Sai Life Sciences

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is headquartered in Hyderabad, India.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 5,224
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAILIFE

Financial Performance

In fiscal year 2026, Sai Life Sciences's revenue was 21.92 billion, an increase of 29.38% compared to the previous year's 16.95 billion. Earnings were 3.49 billion, an increase of 105.08%.

Analyst Summary

According to 7 analysts, the average rating for SAILIFE stock is "Buy." The 12-month stock price target is ₹1,553, which is a decrease of -2.04% from the latest price.

Price Target

₹1,553

(-2.04% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error